WHO ICTRP trial
A randomized study to comparelomustine with lomustine and bevacizumab for…
EUCTR2020-003545-11-DK · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2020-003545-11-DK |
|---|---|
| Public title | A randomized study to comparelomustine with lomustine and bevacizumab for patients with recurrent malignant brain tumors. |
| Scientific title | A randomized phase III trial with lomustine versus lomustine and bevacizumab for patients with recurrent glioblastoma. - DNOG-LOBE-01 |
| Primary sponsor | Rigshospitalet |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no |
| Countries | Denmark |
| Conditions | recurrent glioblastoma MedDRA version: 20.0 Level: PT Classification code 10018337 Term: Glioblastoma multiforme System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases… |
| Interventions | Trade Name: lomustine Product Name: lomustine Pharmaceutical Form: Capsule INN or Proposed INN: lomustine Other descriptive name: LOMUSTINE Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 200- Trade Name… |
| Registration date | Aug 27, 2020 |
| Target size | 168 |
| Secondary IDs | DNOG-LOBE-01 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: